Oncotelic Therapeutics awards 17,796 RSUs tied to unregistered preferred stock issuance
OTLC•RSU award tied to preferred stock issuance
Oncotelic Therapeutics granted 17,796 restricted stock units in an unregistered equity issuance exempt under Securities Act Section 4(a)(2).
Each RSU settles into 1 share of Series A Convertible Preferred Stock, convertible into 1,000 common shares.
Vesting requires a common-stock uplisting to a national exchange by June 30, 2027, then six months of continued service.
The RSUs were issued at no cost, and the awards cover directors, officers, employees, and advisers.
